Study of XL999 in Adults With Solid Tumors

Symphony Evolution

Status and phase: Completed; Phase 1

Conditions: Cancer

Treatments: Drug: XL999

Study type: Interventional

Funder types: Industry

Identifiers

NCT00104117

XL999-001

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced solid tumor
• Cancer that has progressed on currently available therapies
• Life expectancy of >3 months
• Adequate bone marrow, liver, and kidney function
• Willing to use accepted method of contraception during the course of the study
• Negative pregnancy test (females)
• Written informed consent

Exclusion criteria

• Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
• Radiotherapy within 4 weeks of the start of treatment
• Subjects with known brain metastasis
• Uncontrolled medical disorder such as infection or cardiovascular disease
• Subjects known to be HIV positive
• Pregnant or breastfeeding women

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)